Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs
Biotech hopes to counter established Restasis and Xiidra in dry eye with a combination of two approved ophthalmology eye drops, offering quicker onset of action, tolerability and strong efficacy.
You may also be interested in...
Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.
Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending arrival of a generic Restasis throws a curveball into the whole category.
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.